Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

E-Therapeutics Granted Approval For Phase I Trials Of Anti-cancer Drug ETS2101

3/29/2012 2:48 AM ET

Biotechnology company e-Therapeutics Plc (ETX.L) Thursday announced that its plans for Phase-1 trials of its anti-cancer drug ETS2101 have received approvals from the regulatory authorities both in the UK and in the US.

Following the receipt of approvals, the company reaffirmed that enrolment of patients for the Phase-1 trial in both the US and the UK would be commencing shortly.

Professor Malcolm Young, CEO of e-Therapeutics, said: "We remain on track to report the first data from cancer trials with ETS2101 and to advance three further drugs into the clinic by the end of this year."

Click here to receive FREE breaking news email alerts for e-Therapeutics plc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Australia Leading Index Suggests Above-Trend Growth
A leading indicator of Australian economic activity continued to signal above-trend growth for the economy in the coming quarters, a report from Westpac and Melbourne Institute showed Wednesday. The annualized growth rate of the leading index, which indicates the likely pace of economic activity three to nine months into the future, was 5.4 percent in April, comfortably above its long term trend.
Adobe Profit Tops Estimate
Publishing and design software maker Adobe Systems Inc. said Tuesday after the markets closed that its second quarter profit fell 66% from last year, hurt by lower revenue as well as higher costs and expenses. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations and its quarterly revenue was in line with analysts' forecast.
Stocks Show Strong Upward Move Ahead Of Fed Announcement - U.S. Commentary
Stocks showed a strong upward move over the course of the trading day on Tuesday, adding to the gains posted in the previous session. The rally came even as traders expressed some uncertainty ahead of tomorrow's Federal Reserve announcement. The major averages gave back some ground going into the close but remained firmly in positive territory.
FREE Newsletters & Alerts
Breaking News Alerts
Daily Market Briefing
Health
Technology
Biotechnology
signup

Follow RTT
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.
[X]
Copyright © 2013 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service.
Privacy   |   Feedback   |   Sitemap